Dr. Katherine Smith, MD

NPI: 1578504130
Total Payments
$368,290
2021 Payments
$4,331
Companies
3
Transactions
69

Payment Breakdown by Category

Consulting$368,244 (100.0%)
Food & Beverage$46.15 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $368,244 68 100.0%
Food and Beverage $46.15 1 0.0%

Top Paying Companies

Company Total Records Latest Year
Acorda Therapeutics, Inc $329,190 52 $0 (2021)
ASSERTIO THERAPEUTICS, Inc. $38,830 16 $0 (2019)
Emergent Biosolutions Inc. $270.00 1 $0 (2017)

Payment History by Year

Year Amount Transactions Top Company
2021 $4,331 4 Acorda Therapeutics, Inc ($4,331)
2020 $37,982 11 Acorda Therapeutics, Inc ($37,982)
2019 $90,443 26 Acorda Therapeutics, Inc ($59,437)
2018 $79,559 16 Acorda Therapeutics, Inc ($71,735)
2017 $155,974 12 Acorda Therapeutics, Inc ($155,704)

All Payment Transactions

69 individual payment records from CMS Open Payments — Page 1 of 3

Date Company Product Nature Form Amount Type
03/31/2021 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $675.00 General
Category: PARKINSONS DISEASE
03/03/2021 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $2,250.00 General
Category: PARKINSONS DISEASE
02/03/2021 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $731.25 General
Category: PARKINSONS DISEASE
01/06/2021 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $675.00 General
Category: PARKINSONS DISEASE
11/18/2020 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $1,575.00 General
Category: PARKINSONS DISEASE
11/04/2020 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $787.50 General
Category: PARKINSONS DISEASE
10/07/2020 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $1,968.75 General
Category: PARKINSONS DISEASE
09/09/2020 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $7,087.50 General
Category: PARKINSONS DISEASE
07/29/2020 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $3,487.50 General
Category: PARKINSONS DISEASE
07/08/2020 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $2,115.00 General
Category: PARKINSONS DISEASE
06/03/2020 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $1,707.75 General
Category: PARKINSONS DISEASE
04/29/2020 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $3,645.00 General
Category: PARKINSONS DISEASE
03/25/2020 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $4,365.00 General
Category: PARKINSONS DISEASE
02/26/2020 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $7,380.00 General
Category: PARKINSONS DISEASE
01/29/2020 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $3,863.25 General
Category: PARKINSONS DISEASE
12/20/2019 ASSERTIO THERAPEUTICS, Inc. Consulting Fee Cash or cash equivalent $2,220.00 General
12/19/2019 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $4,612.50 General
Category: PARKINSONS DISEASE
12/13/2019 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $2,212.50 General
Category: PARKINSONS DISEASE
12/06/2019 ASSERTIO THERAPEUTICS, Inc. Consulting Fee Cash or cash equivalent $1,900.00 General
11/06/2019 ASSERTIO THERAPEUTICS, Inc. Consulting Fee Cash or cash equivalent $2,310.00 General
10/25/2019 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $2,568.75 General
Category: PARKINSONS DISEASE
10/04/2019 ASSERTIO THERAPEUTICS, Inc. Consulting Fee Cash or cash equivalent $2,250.00 General
09/26/2019 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $3,093.75 General
Category: PARKINSONS DISEASE
08/29/2019 Acorda Therapeutics, Inc INBRIJA (Drug) Consulting Fee Cash or cash equivalent $4,916.25 General
Category: PARKINSONS DISEASE
08/29/2019 ASSERTIO THERAPEUTICS, Inc. Consulting Fee Cash or cash equivalent $3,075.00 General

About Dr. Katherine Smith, MD

Dr. Katherine Smith, MD is a Pediatrics healthcare provider based in Raleigh, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1578504130.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Katherine Smith, MD has received a total of $368,290 in payments from pharmaceutical and medical device companies, with $4,331 received in 2021. These payments were reported across 69 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($368,244).

Practice Information

  • Specialty Pediatrics
  • Location Raleigh, NC
  • Active Since 06/08/2006
  • Last Updated 05/13/2008
  • Taxonomy Code 208000000X
  • Entity Type Individual
  • NPI Number 1578504130

Products in Payments

  • AMPYRA (Drug) $227,439
  • INBRIJA (Drug) $101,751
  • Cosyntropin (Drug) $7,824
  • CNJ-016 (Biological) $270.00

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatrics Doctors in Raleigh